MicroTransponder Raises $65 Million for Vivistim's Stroke Rehabilitation Expansion

In a groundbreaking announcement, MicroTransponder, Inc., a leader in stroke rehabilitation technology, has successfully closed a $65 million Series F financing round. This new funding comes from prominent investors like US Venture Partners (USVP), alongside existing collaborators such as Osage University Partners and GPG Ventures. New investors, including Gilde Healthcare and Longitude Capital, also joined this financing effort. The capital raised will significantly enhance the adoption of MicroTransponder's flagship product, Vivistim® Paired VNS™ System, designed to transform the stroke recovery process for patients.

Vivistim is a groundbreaking intervention that holds the distinction of being the first FDA-approved treatment clinically proven to enable chronic ischemic stroke survivors to regain 2-3 times more upper extremity function than traditional high-intensity stroke therapies. The unique capability of this device lies in its integration with vagus nerve stimulation (VNS) therapies, providing patients with a more effective rehabilitation strategy.

The Mechanism and Effectiveness of Vivistim

Vivistim employs a dual mechanism where an implanted device works in conjunction with a therapist during intensive repetition therapy. By stimulating the vagus nerve, the therapy aims to increase neuroplasticity, which is pivotal for recovery. This method helps stroke survivors achieve remarkable improvements in their daily living skills, from grasping objects to performing fine motor tasks. The positive outcomes of Vivistim therapy have been reinforced by real-world data presented at significant medical conferences, showcasing its effectiveness in reputable stroke centers.

Richard Foust, CEO of MicroTransponder, highlighted the company's commitment to redefining the stroke care continuum.